Showing 7781-7790 of 8648 results for "".
- Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophieshttps://modernod.com/news/trefoil-therapeutics-begins-first-clinical-trial-of-regenerative-treatment-for-patients-with-corneal-endothelial-dystrophies/2478175/Trefoil Therapeutics announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The phase 1/2 trial (INTREPID)
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- Nearly Half of Physicians Believe It Will Take a Year to Get COVID-19 Under Controlhttps://modernod.com/news/nearly-half-of-physicians-believe-it-will-take-a-year-to-get-covid-19-under-control/2478174/The majority of physicians believe COVID-19 won’t be under control until January 2021, and nearly half (49%) expect it will take much longer to get the virus under control, according to a FierceHealthcare
- Why Johnson & Johnson is Investing in This Niche Telehealth Startuphttps://modernod.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare
- Sanofi Enters $3.7-Billion Deal to Buy Principia Biopharmahttps://modernod.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/Sanofi announced Monday a definitive agreement to acquire all of Principia Biopharma’s outstanding stock for $100 per share in cash, representing an equity value of around $3.7 billion, boosting the French drugmaker’s core research areas of autoimmune and allergic diseases. The deal,
- How COVID-19 is Shaking Up Medical Education—For Goodhttps://modernod.com/news/how-covid-19-is-shaking-up-medical-education-for-good/2478168/With COVID-19 shows no signs of letting up soon, leaders at medical schools are adapting their plans for education in the fall to meet the new demands of the pandemic, according to a FierceHealthcare report. That means going digital in an unprecedented way—both in terms of classe
- Comparison of Mask Types Finds Key Differences in Filtrationhttps://modernod.com/news/comparison-of-mask-types-finds-key-differences-in-filtration/2478161/N95 masks that are well past their expiration date or have been used and re-sterilized are acceptable alternatives to standard new single-use N95 masks, new research indicates. But some masks start off with better filtration efficiency than others, according to a Medscape
- EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccinehttps://modernod.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/The European Commission said that it concluded exploratory talks with Johnson & Johnson to buy Ad26.COV2.S, the company’s vaccine candidate against COVID-19. Under the potential deal, once a vaccine has shown to be safe and effective against the novel coronavirus, the Commission s
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T